Annual report
Annual Report 2026
Source: Nse
VILIN BIO MED LTD. (VILINBIO)
SME CapPharma stocks · SME cap · NSE
VILIN BIO MED LTD. operates in Medical Devices, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
₹53.25
+0.00 · +0.00%
Market cap ₹86.2 Cr
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals05 Oct 2026 · screener
Latest result01 Jun, 08:00 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags04 Oct 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
78BullishSMA20 +12.2% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 64
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
VILINBIOD candles · FIT view+45.1%Latest close ₹53.25 on 2026-10-16
Bar
-4.8%
RSI
51
MACD hist
-0.39
52W pos
82%
2026-10-16O ₹55.95H ₹55.95L ₹53.25C ₹53.25Vol 16,000 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
VILINBIONifty PharmaNifty 500
- VILINBIO
- +26.0%
- Nifty 500
- -4.2%
- Nifty Pharma
- -1.0%
- Vs Nifty 500
- +30.2 pp
Chart stats
16 Oct 2026- From 52W high
- -12.6%
- 52W range position
- 82%
- ATR (14)
- 4.6%
- Volume vs 20D
- 0.90x
- Avg traded value
- ₹0.1 Cr
- 20D price channel
- ₹49.7 - ₹60
₹61
₹19 - ₹61
₹2.5
Latest completed session
20-session average
57.3% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · OVERVALUED31
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good55
Revenue +299.5% · PAT NDF YoY
Technical
Bullish78
Price trend and sector-relative-strength timing.
Valuation
Legacy model+6.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence67
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Good · 55/100Rev +300% YoY · margin expansion · +237% QoQ
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹32.6 Cr | +299.5% | +237.5% |
| EBITDA | ₹2.9 Cr | NDF | +741.2% |
| Operating margin | 8.8% | NDF | +525 bps |
| PAT | ₹1.8 Cr | NDF | +1086.7% |
| PAT margin | 5.5% | NDF | +391 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 44.60
- P/B
- 3.04
- EV/EBITDA
- 24.83
- Market Cap
- 86.20Cr
Profitability
- ROE
- 7.51%
- ROCE
- 10.80%
- ROA
- 5.52%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 30.00%
- EPS 5Y
- 74.00%
- Revenue 3Y
- 51.00%
- EPS 3Y
- 16.00%
Balance Sheet
- Debt/Equity
- 0.01
- Interest Coverage
- 45.71×
- Altman Z
- 8.33
- Book Value
- 18.60
Cash Flow
- FCF Yield
- 0.46%
- FCF Positive Y
- 2/5
- OCF
- 0.70 Cr
- EPS TTM
- 1.27
Shareholding
- Promoter Hold
- 56.65%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 89%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 32.6+237.5% vs prev
Net Profit
₹ CrLatest: 1.8+1086.7% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bullish setupTrend is constructive — long-term trend unclear. RSI 51.
- SMA20 rising (~10.9% over last month) — short-term momentum positive.
- RSI(14) at 51 — rising, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 13% off 52W high · 181% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
94
RS percentile
Stage 2 UptrendEstablished S2
1M return
-9.7%
3M return
+20.7%
6M return
+53.7%
1Y return
+106.8%
RS 1D
0
RS 20D
-1
Sector rank
#1
Industry rank
#3
Stage evidence
- Price is 22.9% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +9.0%.
- Both 3-month and 6-month returns are positive.
50-DMA
price above
200-DMA
price above
S2 entered
18 Feb 2026
S2 age
140 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
206 observations
16 Oct 2026Value 203.41-2.95%
RS vs Nifty 500203
Valuation & peers
U-Score 31 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 31 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation3/30
Growth19/25
Quality1/20
Balance Sheet10/15
Cash Flow2/10
Piotroski
7/9 (+5)
Penalties
-9
Raw sum
31
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
31/100 · legacy band OVERVALUED
Positive drivers
- Piotroski is strong at 7/9.
- Growth contributes 19/25 to the score.
- Balance sheet contributes 10/15 to the score.
Main drags
- Penalty bucket subtracts 9 points.
- Quality is weaker at 1/20; verify the latest quarterly trend.
- Valuation is weaker at 3/30; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
44.6
PB
3.0
EV/EBITDA
24.8
ROE
7.5%
ROCE
10.8%
FCF Yield
0.5%
Debt/Equity
0.0
MoS
+6.8%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
31
Previous: 31
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
+6.8%
Previous: +6.8%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
31
31
31
31
31
31
31
31
31
31
31
31
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹23.05
-131.0% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹57.15
+6.8% MoS
PEG
0.88
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
OSELDEVICE
SME
Osel Devices Ltd.
Medical Devices
match 152
60
21.1
18.7%
+53%
UNDERVALUED
POLYMED
Large
Poly Medicure Limited
Medical Devices
match 148
32
50.1
9.0%
-11%
WATCHLIST
GML
SME
Galaxy Medicare Ltd.
Medical Devices
match 134
67
8.3
10.8%
+81%
UNDERVALUED
ANONDITA
SME
Anondita Medicare Ltd.
Medical Devices
match 130
59
61.0
40.2%
-72%
FAIR VALUE
INFLUX
SME
Influx Healthtech Ltd.
Medical Devices
match 126
27
31.8
19.0%
-296%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
VILIN BIO MED LTD. operates in Medical Devices, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
67Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 52nd percentile of the scored universe and 39th percentile within Pharma. Main check: results consistency is weak at 29/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
0 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
52nd percentile
overall median 67 · Pharma: 39th pctile, median 70 · SME: 66th pctile, median 64
Evidence depth
Financial-only
0 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
68
acceptable · holding, pledge, alignment
Cash flow
65
acceptable · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
68
acceptable · capital discipline
Results
29
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 56.7%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 0.6%.
- ▸Debt/equity is 0.01.
Trust risks
- ▸Promoter holding fell 7.2%.
- ▸4 latest quarters had PAT decline worse than 25% YoY.
- ▸ROE is low at 7.5%.
- ▸0/4 latest quarters had positive YoY PAT growth.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching VILIN BIO MED LTD.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual report
Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.